Dr. Jingfeng Li is a distinguished molecular biologist and biotechnology expert with extensive experience in cancer research and gene therapy innovation. He currently serves as a Professor at the School of Pharmacy, Yantai University, where he leads pioneering research on the molecular mechanisms underlying the tumor-suppressive effects of oncolytic HSV1 viruses across various solid tumors. Concurrently, as Chief Science Officer, Chief Scientist, and Deputy General Manager at Beijing WellGene Company Ltd., Dr. Li oversees the strategic development and implementation of advanced gene therapy pipelines, guiding the company’s research, innovation, and product development in alignment with global biomedical trends. His career reflects a deep commitment to translational research, having previously held academic positions at The Ohio State University, where his team investigated the molecular pathways driving HPV-associated head, neck, and cervical cancers, and conducted significant studies on transposon epigenetics and hereditary disease gene cloning. Earlier in his career, at the National Cancer Institute (NIH), he focused on DNA methylation and retrotransposon polymorphisms, contributing to foundational insights in tumor biology. Dr. Li’s entrepreneurial endeavors include founding Singlebase LLC in the United States, where he developed genetic testing products for targeted lung cancer therapy, including fusion detection and resistance mutation assays. A Ph.D. graduate from the Karolinska Institute in Cell and Tumor Biology, Dr. Li has been recognized for his leadership and innovation, notably as part of Beijing’s Overseas Talent Gathering Project and as a Yicheng Outstanding Talent. His work has been presented at major international conferences, including the International Papillomavirus Conference and the CGCS Summit on Cell and Gene Therapy, reflecting his global reputation in advancing the frontiers of molecular oncology and gene therapy.